MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 533327 | Name: A-68930 hydrochloride
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

A-68930 hydrochloride is a selective D1 dopamine receptor agonist, ameliorates Aβ1-42-induced cognitive impairment and neuroinflammation in mice, showing promise in treating Alzheimer's disease. Additionally, A-68930 (10-50 microg/ml) inhibits the gastric H(+) K(+)-ATPase activity comparably to omeprazole.

Chemical Structure

A-68930 hydrochloride
A-68930 hydrochloride
CAS#130465-39-3

Theoretical Analysis

MedKoo Cat#: 533327

Name: A-68930 hydrochloride

CAS#: 130465-39-3

Chemical Formula: C16H18ClNO3

Exact Mass: 307.0975

Molecular Weight: 307.77

Elemental Analysis: C, 62.44; H, 5.90; Cl, 11.52; N, 4.55; O, 15.59

Price and Availability

Size Price Availability Quantity
10mg USD 450.00 2 Weeks
50mg USD 1,350.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
A-68930 hydrochloride; A 68930 hydrochloride; A68930 hydrochloride
IUPAC/Chemical Name
cis-1-(Aminomethyl)-3-phenylisochroman-5,6-diol hydrochloride
InChi Key
PQPGUUQPTSMLKU-CTHHTMFSSA-N
InChi Code
InChI=1S/C16H17NO3.ClH/c17-9-15-11-6-7-13(18)16(19)12(11)8-14(20-15)10-4-2-1-3-5-10;/h1-7,14-15,18-19H,8-9,17H2;1H/t14-,15-;/m1./s1
SMILES Code
OC1=C(O)C=CC2=C1C[C@H](C3=CC=CC=C3)O[C@@H]2CN.[H]Cl
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 307.77 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Martin YC. The Discovery of Novel Selective D1 Dopaminergic Agonists: A-68930, A-77636, A-86929, and ABT-413. Int J Med Chem. 2011;2011:424535. doi: 10.1155/2011/424535. Epub 2011 Mar 24. PMID: 25954518; PMCID: PMC4412209. 2: Cheng ZY, Xia QP, Hu YH, Wang C, He L. Dopamine D1 receptor agonist A-68930 ameliorates Aβ1-42-induced cognitive impairment and neuroinflammation in mice. Int Immunopharmacol. 2020 Nov;88:106963. doi: 10.1016/j.intimp.2020.106963. Epub 2020 Sep 10. PMID: 33182028. 3: Cheng ZY, Hu YH, Xia QP, Wang C, He L. DRD1 agonist A-68930 improves mitochondrial dysfunction and cognitive deficits in a streptozotocin-induced mouse model. Brain Res Bull. 2021 Oct;175:136-149. doi: 10.1016/j.brainresbull.2021.07.015. Epub 2021 Jul 17. PMID: 34284074. 4: AI-Naser HA, Cooper SJ. A-68930, a novel, potent dopamine D1 receptor agonist: a microstructural analysis of its effects on feeding and other behaviour in the rat. Behav Pharmacol. 1994 Apr;5(2):210-218. PMID: 11224270. 5: Rasheed N, Ahmad A, Singh N, Singh P, Mishra V, Banu N, Lohani M, Sharma S, Palit G. Differential response of A 68930 and sulpiride in stress-induced gastric ulcers in rats. Eur J Pharmacol. 2010 Sep 15;643(1):121-8. doi: 10.1016/j.ejphar.2010.06.032. Epub 2010 Jun 28. PMID: 20599913. 6: Jiang W, Huang Y, He F, Liu J, Li M, Sun T, Ren W, Hou J, Zhu L. Dopamine D1 Receptor Agonist A-68930 Inhibits NLRP3 Inflammasome Activation, Controls Inflammation, and Alleviates Histopathology in a Rat Model of Spinal Cord Injury. Spine (Phila Pa 1976). 2016 Mar;41(6):E330-4. doi: 10.1097/BRS.0000000000001287. PMID: 26966979. 7: Isacson R, Kull B, Wahlestedt C, Salmi P. A 68930 and dihydrexidine inhibit locomotor activity and d-amphetamine-induced hyperactivity in rats: a role of inhibitory dopamine D(1/5) receptors in the prefrontal cortex? Neuroscience. 2004;124(1):33-42. doi: 10.1016/j.neuroscience.2003.11.016. PMID: 14960337. 8: Jiang W, Li M, He F, Bian Z, Liu J, He Q, Wang X, Sun T, Zhu L. Dopamine D1 receptor agonist A-68930 inhibits NLRP3 inflammasome activation and protects rats from spinal cord injury-induced acute lung injury. Spinal Cord. 2016 Nov;54(11):951-956. doi: 10.1038/sc.2016.52. Epub 2016 Apr 12. PMID: 27067657. 9: Nergårdh R, Oerther S, Fredholm BB. Differences between A 68930 and SKF 82958 could suggest synergistic roles of D1 and D5 receptors. Pharmacol Biochem Behav. 2005 Nov;82(3):495-505. doi: 10.1016/j.pbb.2005.09.017. Epub 2005 Nov 28. PMID: 16318870. 10: Christie MI, Smith GW. Cardiovascular and renal hemodynamic effects of A-68930 in the conscious dog: a comparison with fenoldopam. J Pharmacol Exp Ther. 1994 Feb;268(2):565-70. PMID: 7906731. 11: Salmi P, Ahlenius S. Sedative effects of the dopamine D1 receptor agonist A 68930 on rat open-field behavior. Neuroreport. 2000 Apr 27;11(6):1269-72. doi: 10.1097/00001756-200004270-00025. PMID: 10817605. 12: Johnson KB, Criswell HE, Jensen KF, Simson PE, Mueller RA, Breese GR. Comparison of the D1-dopamine agonists SKF-38393 and A-68930 in neonatal 6-hydroxydopamine-lesioned rats: behavioral effects and induction of c-fos-like immunoreactivity. J Pharmacol Exp Ther. 1992 Aug;262(2):855-65. PMID: 1354257. 13: Deveney AM, Waddington JL. Comparison of the new atypical antipsychotics olanzapine and ICI 204,636 with clozapine on behavioural responses to the selective "D1-like" dopamine receptor agonist A 68930 and selective "D2-like" agonist RU 24213. Psychopharmacology (Berl). 1996 Mar;124(1-2):40-9. doi: 10.1007/BF02245604. PMID: 8935799. 14: Liu J, Jin Y, Wang B, Wang Y, Zuo S, Zhang J. Dopamine D1 receptor alleviates doxorubicin-induced cardiac injury by inhibiting NLRP3 inflammasome. Biochem Biophys Res Commun. 2021 Jul 5;561:7-13. doi: 10.1016/j.bbrc.2021.04.098. Epub 2021 May 13. PMID: 33992835. 15: Rasheed N, Ahmad A, Pandey CP, Chaturvedi RK, Lohani M, Palit G. Differential response of central dopaminergic system in acute and chronic unpredictable stress models in rats. Neurochem Res. 2010 Jan;35(1):22-32. doi: 10.1007/s11064-009-0026-5. Epub 2009 Jul 1. PMID: 19568932. 16: Daly SA, Waddington JL. The effects of clozapine on behavioural responses to the selective 'D1-like' dopamine receptor agonist, A 68930, and to the selective 'D2-like' agonist, RU 24213. Br J Pharmacol. 1994 Nov;113(3):839-44. doi: 10.1111/j.1476-5381.1994.tb17069.x. PMID: 7858875; PMCID: PMC1510419. 17: Daly SA, Waddington JL. Behavioural evidence for "D-1-like" dopamine receptor subtypes in rat brain using the new isochroman agonist A 68930 and isoquinoline antagonist BW 737C. Psychopharmacology (Berl). 1993;113(1):45-50. doi: 10.1007/BF02244332. PMID: 7862827. 18: Gronier B, Waters S, Ponten H. The dopaminergic stabilizer pridopidine increases neuronal activity of pyramidal neurons in the prefrontal cortex. J Neural Transm (Vienna). 2013 Sep;120(9):1281-94. doi: 10.1007/s00702-013-1002-4. Epub 2013 Mar 7. PMID: 23468085. 19: Salmi P. Independent roles of dopamine D1 and D2/3 receptors in rat thermoregulation. Brain Res. 1998 Jan 19;781(1-2):188-93. doi: 10.1016/s0006-8993(97)01229-8. PMID: 9507118. 20: Kurokawa K, Mizuno K, Ohkuma S. Increase of ryanodine receptors by dopamine D1 receptors is negatively regulated by γ-aminobutyric acid type B receptors in primary cultures of mouse cerebral cortical neurons. J Neurosci Res. 2012 Aug;90(8):1626-38. doi: 10.1002/jnr.23058. Epub 2012 Apr 14. PMID: 22504960.